Status:
COMPLETED
Acetyl-L-Carnitine In Severe Hepatic Encephalopathy
Lead Sponsor:
University of Catania
Conditions:
Hepatic Encephalopathy (Grade 3 of the West Haven Grading Scale)
Eligibility:
All Genders
40-65 years
Phase:
NA
Brief Summary
To assess the clinical efficacy of ALC in the treatment of severe hepatic encephalopathy (grade 3 of the West Haven grading scale), we performed a randomised, double blind placebo-controlled study adm...
Eligibility Criteria
Inclusion
- patients with severe hepatic encephalopathy (grade 3 of the West Haven grading scale) with hepatic cirrhosis
Exclusion
- Patients with a history of recent alcohol abuse, patients using psychotropic drugs (e.g., antipsychotics, interferon, benzodiazepines, anti-epileptics, sedatives and antidepressants)
- Other exclusion criteria were the following: major complications of portal hypertension, such as gastrointestinal blood loss, hepatorenal syndrome or bacterial peritonitis; acute superimposed liver injury;patients with metabolic disorders such as diabetes mellitus, unbalanced heart failure and/or respiratory failure or end-stage renal disease; any additional precipitating factors such as high protein intake (additional high-protein meals), constipation; illiteracy.
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01223768
Start Date
July 1 2002
End Date
December 1 2005
Last Update
October 19 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cannizzaro Hospital
Catania, Italy, 95126